BCDA
Price
$0.38
Change
-$0.00 (-0.00%)
Updated
Apr 24, 6:59 PM EST
13 days until earnings call
SVRA
Price
$4.24
Change
-$0.45 (-9.59%)
Updated
Apr 24, 6:59 PM EST
14 days until earnings call
Ad is loading...

Analysis and predictions BCDA vs SVRA

Header iconBCDA vs SVRA Comparison
Open Charts BCDA vs SVRABanner chart's image
BioCardia
Price$0.38
Change-$0.00 (-0.00%)
Volume$47.03K
CapitalizationN/A
Savara
Price$4.24
Change-$0.45 (-9.59%)
Volume$492.55K
CapitalizationN/A
View a ticker or compare two or three
BCDA vs SVRA Comparison Chart

Loading...

BCDADaily Signal changed days agoGain/Loss if shorted
 
Show more...
SVRADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
BCDA vs. SVRA commentary
Apr 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCDA is a Hold and SVRA is a Hold.

COMPARISON
Comparison
Apr 25, 2024
Stock price -- (BCDA: $0.38 vs. SVRA: $4.24)
Brand notoriety: BCDA and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCDA: 19% vs. SVRA: 124%
Market capitalization -- BCDA: $10.2M vs. SVRA: $585.75M
BCDA [@Biotechnology] is valued at $10.2M. SVRA’s [@Biotechnology] market capitalization is $585.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $567.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCDA’s FA Score shows that 0 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • BCDA’s FA Score: 0 green, 5 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, SVRA is a better buy in the long-term than BCDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCDA’s TA Score shows that 4 TA indicator(s) are bullish while SVRA’s TA Score has 4 bullish TA indicator(s).

  • BCDA’s TA Score: 4 bullish, 3 bearish.
  • SVRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BCDA is a better buy in the short-term than SVRA.

Price Growth

BCDA (@Biotechnology) experienced а +3.10% price change this week, while SVRA (@Biotechnology) price change was -14.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.53%. For the same industry, the average monthly price growth was -8.76%, and the average quarterly price growth was +1259.25%.

Reported Earning Dates

BCDA is expected to report earnings on Aug 07, 2024.

SVRA is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (-1.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for BCDA with price predictions.
OPEN
A.I.dvisor published
a Summary for SVRA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SVRA($586M) has a higher market cap than BCDA($10.2M). SVRA YTD gains are higher at: -9.787 vs. BCDA (-42.864).
BCDASVRABCDA / SVRA
Capitalization10.2M586M2%
EBITDAN/AN/A-
Gain YTD-42.864-9.787438%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
BCDA vs SVRA: Fundamental Ratings
BCDA
SVRA
OUTLOOK RATING
1..100
862
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6544
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCDA's Valuation (56) in the null industry is in the same range as SVRA (75) in the Biotechnology industry. This means that BCDA’s stock grew similarly to SVRA’s over the last 12 months.

BCDA's Profit vs Risk Rating (100) in the null industry is in the same range as SVRA (100) in the Biotechnology industry. This means that BCDA’s stock grew similarly to SVRA’s over the last 12 months.

SVRA's SMR Rating (97) in the Biotechnology industry is in the same range as BCDA (100) in the null industry. This means that SVRA’s stock grew similarly to BCDA’s over the last 12 months.

SVRA's Price Growth Rating (44) in the Biotechnology industry is in the same range as BCDA (65) in the null industry. This means that SVRA’s stock grew similarly to BCDA’s over the last 12 months.

SVRA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCDA (100) in the null industry. This means that SVRA’s stock grew similarly to BCDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCDASVRA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend about 1 month ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Ad is loading...
BCDADaily Signal changed days agoGain/Loss if shorted
 
Show more...
SVRADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALTO1.960.05
+2.62%
Alto Ingredients
IART29.38N/A
N/A
Integra LifeSciences Holdings Corp
RTO26.66-0.08
-0.30%
Rentokil Initial plc
AMBC14.54-0.10
-0.68%
Ambac Financial Group
ERNA1.74-0.22
-11.22%
Eterna Therapeutics

BCDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCDA has been loosely correlated with LABP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BCDA jumps, then LABP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCDA
1D Price
Change %
BCDA100%
+0.93%
LABP - BCDA
35%
Loosely correlated
+0.13%
LYEL - BCDA
30%
Poorly correlated
-5.74%
MDGL - BCDA
29%
Poorly correlated
-6.29%
INO - BCDA
28%
Poorly correlated
-2.03%
STOK - BCDA
28%
Poorly correlated
+3.64%
More

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with PCVX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then PCVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
-9.59%
PCVX - SVRA
36%
Loosely correlated
-0.95%
FOLD - SVRA
36%
Loosely correlated
-1.59%
ELVN - SVRA
35%
Loosely correlated
+0.69%
SCPH - SVRA
35%
Loosely correlated
-2.39%
HLVX - SVRA
35%
Loosely correlated
-1.80%
More